動脈硬化性心血管疾患における集積誘発発光源の最近の進歩
Yue Lan1, Sheng'e Su1, Jiageng Cai2
1The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, 100191, China.
Advanced healthcare materials
|September 4, 2025
まとめ
集積誘発発光源 (AIEgens) は,動脈硬化性心血管疾患 (ASCVD) の診断と治療に有望である. このレビューでは,ASCVDのセンシング,イメージング,および治療におけるAIEgenの特性とアプリケーションを強調しています.
科学分野:
- * ナノテクノロジーと材料科学
- * バイオメディカルエンジニアリング
- * 薬剤化学
背景:
- * 動脈硬化性心血管疾患 (ASCVD) は,世界の主要な死因です.
- * 血栓形成は動脈壁に脂質が蓄積され,重篤な合併症を引き起こします.
- * 新しい診断薬と治療薬はASCVDの管理に不可欠です.
研究 の 目的:
- * ASCVDの集積誘発発光源 (AIEgens) の最近の進歩をレビューする.
- * AIEgenの特性とASCVD管理のための設計を調査する.
- * ASCVDバイオマーカーセンシング,イメージング,および治療におけるAIEgenのアプリケーションを要約します.
主な方法:
- * ASCVDにおけるAIEゲン研究の体系的な文献レビュー (過去5年)
- * AIEゲンの特性分析:光,光安定性,生物適合性
- * センシング,イメージング,治療におけるAIEgenアプリケーションの評価
主要な成果:
- * AIEgensは,バイオメディカルアプリケーションに理想的な,集積状態で強化された光を示します.
- * 適合したAIEgen設計により,ASCVDバイオマーカーの効果的な検出とイメージングが容易になります.
- * AIEゲンはASCVDの治療戦略に潜在性を示しています.
結論:
- * AIEgensはASCVDの診断と治療のための有望な材料のクラスです.
- * 現在の課題に対処し,AIEgenの有用性を最適化するには,さらなる研究が必要です.
- * 将来の見通しには,ASCVDの総合的な管理のためのAIEゲンの強化開発が含まれています.
さらに関連する動画
関連する概念動画
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...